Physician profile
Jay D Fawver
NPI 1164457404
$1,420,273.50
in general payments reported to CMS, 2019-2025
32 companies · $306K in 2025
The $306K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151K · 2020: $43K · 2021: $98K · 2022: $251K · 2023: $317K · 2024: $254K · 2025: $306K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $411K · Consulting Fee: $235K · Travel and Lodging: $125K · Honoraria: $90K · Food and Beverage: $16K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $411,332.50 |
| Consulting Fee | $235,005.75 |
| Travel and Lodging | $125,294.25 |
| Honoraria | $90,344.00 |
| Food and Beverage | $15,553.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $659,406.49 | 2019-2025 | Spravato |
| Axsome Therapeutics, INC. | $379,387.27 | 2022-2025 | Auvelity |
| Alkermes, INC. | $258,022.50 | 2022-2025 | Lybalvi, Aristada |
| Takeda Pharmaceuticals U.S.A., INC. | $56,884.79 | 2019-2023 | Trintellix |
| Biogen, INC. | $25,932.17 | 2024-2025 | Zurzuvae |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17,338.64 | 2020-2025 | Caplyta |
| H. Lundbeck A S | $12,463.23 | 2019 | |
| Janssen Scientific Affairs, LLC | $4,701.09 | 2024-2025 | Spravato |
| Sage Therapeutics, LLC | $3,773.98 | 2022 | |
| Lundbeck LLC | $290.75 | 2019-2023 | Rexulti |
| Neurocrine Biosciences, INC. | $243.37 | 2019-2023 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $241.19 | 2019-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $233.65 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $233.23 | 2019-2021 | |
| Bausch Health US, LLC | $198.90 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $164.65 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $112.78 | 2019-2023 | Uzedy |
| Abbvie INC. | $90.73 | 2021-2023 | |
| Arbor Pharmaceuticals, INC. | $77.10 | 2019-2021 | |
| Shire North American Group INC | $72.53 | 2019 | |
| Eisai INC. | $65.78 | 2020-2021 | |
| Allergan, INC. | $57.92 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $51.89 | 2019-2020 | |
| Corium, LLC | $51.09 | 2022-2023 | Azstarys, Azstarys |
| Avanir Pharmaceuticals, INC. | $39.07 | 2019 | |
| Merck Sharp & Dohme LLC | $28.71 | 2021 | |
| Noven Therapeutics, LLC | $24.30 | 2023 | Xelstrym |
| Supernus Pharmaceuticals, INC. | $23.87 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $19.25 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.17 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.54 | 2019 | |
| Amgen INC. | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Fawver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.